Given a question and a context passage, generate the answer having the word or phrase from the context passage. Here, the answer should be a shortest continous span from the passage.

Example Input: Context: Future Life Pets By DogTown Media, LLC Open iTunes to buy and download apps. *Price: $2.99 *Category: Lifestyle *Updated: Jan 07, 2012 *Version: 1.1 *Size: 36.3 MB *Language: English *Seller: DOG TOWN MEDIA *(c) DogTown Media LLC Description DISCOVER FUTURE LIFETIMES WITH YOUR PETS You can be transported into the future to be reunited with your pet in another place and time. As an internationally recognized psychic and best-selling author, Anne Jirsch will be your guide in this fascinating meditation game. Future Life Pets will take you into a state of deep relaxation to help you understand this special condition. With expert hypnosis you can discover how your paths will cross in your future lifetime. WHAT PEOPLE ARE SAYING "I immediately saw I was riding a tall black and white horse and you've guessed it --it was my dog and this time he was bigger than ever." --Mike from Kansas City. "Seeing both my cats in the future lifetime has given me so much joy. They are both cats again next time around, only a lot bigger and smoother. I clearly saw them both lie by my feet just as they do right now." --Felicity from Manchester, UK. The regular buyers of Anne's products include heads of industry, politicians, and celebrities of all kinds. She is a world famous psychic and author of three books Instant Intuition, The Future is Yours, and Cosmic Energy. More than a billion people in the world believe in the truth of meditation, through which we'll gain a greater understanding of our pets and ourselves. Prepare for the experience as the results are astonishing. 
 Question: If we want to use the app of Future Life Pets, what kind of language should we know?
Example Output: english

Example Input: Context: Spleen tyrosine kinase (Syk) is an important modulator of immune signaling. The objective of this phase 2 study was to evaluate the efficacy and safety of R788, an oral inhibitor of Syk, in patients with active rheumatoid arthritis despite methotrexate therapy. We enrolled 457 patients who had active rheumatoid arthritis despite long-term methotrexate therapy in a 6-month, double-blind, placebo-controlled trial. The primary outcome was the American College of Rheumatology (ACR) 20 response (which indicates at least a 20% reduction in the number of both tender and swollen joints and improvement in at least three of five other criteria) at month 6. R788, at a dose of 100 mg twice daily and at a dose of 150 mg once daily, was significantly superior to placebo at month 6 (ACR 20 response rates of 67% and 57%, respectively, vs. 35%; P<0.001 for the comparison of both doses with placebo). It was also significantly superior with respect to ACR 50, which indicates at least a 50% improvement (43% and 32% vs. 19%; P<0.001 for the comparison of the 100-mg dose with placebo, P=0.007 for the comparison of the 150-mg dose with placebo) and ACR 70 (28% and 14% vs. 10%; P<0.001 for the comparison of the 100-mg dose with placebo, P=0.34 for the comparison of the 150-mg dose with placebo). A clinically significant effect was noted by the end of the first week of treatment. Adverse effects included diarrhea (in 19% of subjects taking the 100-mg dose of R788 vs. 3% of those taking placebo), upper respiratory infections (14% vs. 7%), and neutropenia (6% vs. 1%). R788 was associated with an increase in systolic blood pressure of approximately 3 mm Hg between baseline and month 1, as compared with a decrease of 2 mm Hg with placebo; 23% of the patients taking R788 vs. 7% of the patients receiving placebo required the initiation of or a change in antihypertensive therapy. In this phase 2 study, a Syk inhibitor reduced disease activity in patients with rheumatoid arthritis; adverse events included diarrhea, hypertension, and neutropenia. Additional studies will be needed to further assess the safety and efficacy of Syk-inhibition therapy in patients with rheumatoid arthritis. (Funded by Rigel; ClinicalTrials.gov number, NCT00665925.) 
 Question: Which enzyme is inhibited by a drug fostamatinib?
Example Output: spleen tyrosine kinase

Example Input: Context: Riociguat (Adempas(®)), an oral first-in-class soluble guanylate cyclase (sGC) stimulator, is under global development by Bayer Healthcare Pharmaceuticals Inc. for the treatment of adult patients with inoperable or chronic/persistent chronic thromboembolic pulmonary hypertension (CTEPH) and for the treatment of adult patients with pulmonary arterial hypertension (PAH). The drug directly stimulates sGC in a nitric oxide independent manner, thereby increasing the sensitivity of sGC to nitric oxide, leading to increased cyclic guanosine monophosphate generation (a key signalling molecule involved in regulating vascular tone, proliferation, fibrosis and inflammation). Riociguat is the world's first approved pharmacotherapy for CTEPH, with its first global approval in this indication occurring in Canada. It has subsequently been approved in the USA for the treatment of patients with CTEPH and also received its first global approval in patients with PAH in the USA. It is undergoing regulatory review for these indications in Europe and for use in patients with CTEPH in Japan. This article summarizes the milestones in the development of riociguat, leading to its first global approvals in patients with CTEPH and PAH. 
 Question: What is generic name of drug Adempas?
Example Output:
riociguat